PURPOSE OF REVIEW: Endometrial cancer is the most common gynaecological malignancy in the western world. Two clinicopathological subtypes are recognized: type I (endometrioid) and type II (nonendometrioid) carcinomas. This review describes the molecular alterations in endometrial cancer and how this knowledge is leading to the development of novel treatments in this area. RECENT FINDINGS: Molecularly targeted agents have entered clinical trials in endometrial cancer. So far, mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic agents appear promising and are being pursued further in addition to other targeted approaches. SUMMARY: The clinicopathological and molecular heterogeneity of endometrial cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer.
PURPOSE OF REVIEW: Endometrial cancer is the most common gynaecological malignancy in the western world. Two clinicopathological subtypes are recognized: type I (endometrioid) and type II (nonendometrioid) carcinomas. This review describes the molecular alterations in endometrial cancer and how this knowledge is leading to the development of novel treatments in this area. RECENT FINDINGS: Molecularly targeted agents have entered clinical trials in endometrial cancer. So far, mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic agents appear promising and are being pursued further in addition to other targeted approaches. SUMMARY: The clinicopathological and molecular heterogeneity of endometrial cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer.
Authors: Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-01-20 Impact factor: 5.482
Authors: Rebecca A Previs; Guillermo N Armaiz-Pena; Cristina Ivan; Heather J Dalton; Rajesha Rupaimoole; Jean M Hansen; Yasmin Lyons; Jie Huang; Monika Haemmerle; Michael J Wagner; Kshipra M Gharpure; Archana S Nagaraja; Justyna Filant; Michael H McGuire; Kyunghee Noh; Piotr L Dorniak; Sarah L Linesch; Lingegowda S Mangala; Sunila Pradeep; Sherry Y Wu; Anil K Sood Journal: J Natl Cancer Inst Date: 2017-07-01 Impact factor: 13.506
Authors: Igor Govorov; Sanaz Attarha; Larysa Kovalevska; Emil Andersson; Elena Kashuba; Miriam Mints Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 2.339